Paul Hastings Advised Semnur Pharmaceuticals in $2.5B SPAC Merger Agreement With Denali Capital Acquisition
September 04, 2024
September 04, 2024
LOS ANGELES, California, Sept. 4 -- Paul Hastings, a law firm, issued the following news:
Paul Hastings LLP advised Semnur Pharmaceuticals, Inc., a wholly owned subsidiary of Scilex Holding Company (Nasdaq: SCLX) and Denali Capital Acquisition Corp. (Nasdaq: DECA), in the signing of an agreement and plan of merger for a proposed business combination, for a pre-transaction equity value of Semnur of $2.5 billion.
Semnur is a clinical-late-stage specialty pharmaceutical co . . .
Paul Hastings LLP advised Semnur Pharmaceuticals, Inc., a wholly owned subsidiary of Scilex Holding Company (Nasdaq: SCLX) and Denali Capital Acquisition Corp. (Nasdaq: DECA), in the signing of an agreement and plan of merger for a proposed business combination, for a pre-transaction equity value of Semnur of $2.5 billion.
Semnur is a clinical-late-stage specialty pharmaceutical co . . .